• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Organisation › Details

Biocartis (Group)

Biocartis aims to improve healthcare outcomes by enabling the practice of personalized medicine anywhere, anytime. Biocartis' ambition is to establish a new gold standard in diagnostic testing. Biocartis provides innovative research and diagnostic systems with multiplex detection and simplified workflows which require less hands-on time and minimize sample requirements (especially for tumor biopsies). Additionally, Biocartis develops assays which have high clinical utility and compelling health economic value. Oncology is the primary focus of Biocartis as this is one of the greatest unmet needs for personalized medicine. Biocartis is well suited to address the growing need for individualized diagnosis and treatment of cancer patients. Biocartis is a rapidly growing company; to date Biocartis staff includes over 140 people. The company has raised in total EUR 125 million in equity. *

 

	Start	2007-01-01 established
	Industry	molecular diagnostics
	Industry 2	cancer test
	Person	Pauwels, Rudi (Biocartis 201111 Executive Chairman before 201002–201111 CEO)
	Person 2	Welten, Ewoud (Biocartis 201607 CFO)
	Region	Mechelen
	Country	Belgium
	Street	11 B3 Gen. De Wittelaan
	City	2800 Mechelen
	Tel	+32-15-632-600
		Address record changed: 2016-11-22
Basic data	Employees	D: 101 to 500 (2018-12-31)
	Currency	EUR
	Annual sales	28,651,000 (operating income, consolidated (2018) 2018-12-31)
	Profit	-48,153,000 (2018-12-31)
	Cash	63,539,000 (2018-03-31)
		* Document for �About Section�: Biocartis S.A.. (12/5/12). "Press Release: Biocartis Announces Commercial Launch of a New Biomarker Analysis Platform". Lausanne.
		Record changed: 2019-04-23

Advertisement

More documents for Biocartis (Group)

• [1] Biocartis Group N.V.. (6/1/19). "Press Release: Biocartis and Kite Sign Agreement for Development of Assays Supporting Kite's Therapies". Mechelen....
• [2] Biocartis Group N.V.. (4/25/19). "Press Release: Biocartis Q1 2019 Business Update". Mechelen....
• [3] Biocartis Group N.V.. (4/23/19). "Press Release: Biocartis Announces Global Collaboration with Covance". Mechelen....
• [4] Biocartis Group N.V.. (1/23/19). "Press Release: Biocartis Successfully Raises EUR 55.50 Milion in an Equity Placement [NOT FOR US, AU, CA, JP, ZA, et al.]". Mechelen....
• [5] Biocartis Group N.V.. (1/23/19). "Press Release: Biocartis Launches Equity Placement [NOT FOR US, AU, CA, JP, ZA, et al.]". Mechelen....
• [6] Biocartis Group N.V.. (1/23/19). "Press Release: Biocartis Upsizes Its Equity Placement Due to Significant Demand [NOT FOR US, AU, CA, JP, ZA, et al.]". Mechelen....
• [7] Biocartis Group N.V.. (12/3/18). "Press Release: Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla Oncotype DX Genomic Prostate Score Test". Redwood City, CA & Mechelen....
• [8] Biocartis Group N.V.. (11/29/18). "Press Release: Biocartis and AstraZeneca Enter into Agreement Aimed at Faster Lung Cancer Biomarker Results". Mechelen....
• [9] Biocartis Group N.V.. (9/3/18). "Press Release: Biocartis and Wondfo Announce Joint Venture for Commercialization of Idylla Platform in China". Mechelen & Guangzhou....
• [10] Biocartis Group N.V.. (8/28/18). "Press Release: Biocartis Obtains Exclusive Worldwide License Rights for EGFR Ectodomain Mutations Determining Response to Targeted Colorectal Cancer Therapy". Mechelen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2019. Made in Germany.